January 6, 2022
Life Sciences
  • According to a Stat News review, major health care systems are not offering Aduhelm, Biogen Inc.’s controversial Alzheimer’s disease drug. The review identified 15 additional academic medical centers that aren’t prescribing it, including seven that have formally declined to provide the drug. Biogen has said it expects pickup of the drug would improve if Medicare administrators decide to cover the costly treatment. A decision is expected by next week. (Article here)